WO2004063168A1 - Process for preparing substituted imidazole derivatives and intermediates used in the process - Google Patents

Process for preparing substituted imidazole derivatives and intermediates used in the process Download PDF

Info

Publication number
WO2004063168A1
WO2004063168A1 PCT/FI2004/000004 FI2004000004W WO2004063168A1 WO 2004063168 A1 WO2004063168 A1 WO 2004063168A1 FI 2004000004 W FI2004000004 W FI 2004000004W WO 2004063168 A1 WO2004063168 A1 WO 2004063168A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
halogen
process according
ethyl
Prior art date
Application number
PCT/FI2004/000004
Other languages
French (fr)
Inventor
Päivi JUUJÄRVI
Seppo Parhi
Jaana Karjalainen
Original Assignee
Oy Juvantia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2006500148A priority Critical patent/JP4592680B2/en
Application filed by Oy Juvantia Pharma Ltd filed Critical Oy Juvantia Pharma Ltd
Priority to CA2511969A priority patent/CA2511969C/en
Priority to US10/537,177 priority patent/US7223871B2/en
Priority to MXPA05007217A priority patent/MXPA05007217A/en
Priority to AU2004203941A priority patent/AU2004203941B2/en
Priority to DE602004020050T priority patent/DE602004020050D1/en
Priority to BR0406676-6A priority patent/BRPI0406676A/en
Priority to NZ539831A priority patent/NZ539831A/en
Priority to DK04700707T priority patent/DK1581504T3/en
Priority to EP04700707A priority patent/EP1581504B1/en
Publication of WO2004063168A1 publication Critical patent/WO2004063168A1/en
Priority to IL168452A priority patent/IL168452A/en
Priority to NO20053712A priority patent/NO330965B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms

Definitions

  • the present invention relates to a new process for preparing substituted imidazole derivatives of formula (I) and acid addition salts thereof,
  • Y is -CH 2 - or -CO-
  • Ri is H, halogen or hydroxy
  • R 2 is H or halogen
  • R 3 is H or lower alkyl.
  • the invention also relates to intermediates used in the process and to their preparation.
  • the compounds of the above-mentioned formula (I) are highly selective and long-acting antagonists of ⁇ 2 -adrenoceptors and they have a good peroral bioavailability. The compounds are especially valuable in the treatment of cognitive disorders.
  • Compounds of formula (I) have been described in patent publication EP 0 618 906 B1. Specific examples of such compounds are 4-(2-ethyl-5-fluoroindan-2-yl)-1 H-imidazole and 4-(5- fluoroindan-2-yl)-1 H-imidazole.
  • Publication EP 0 310 745 B1 discloses a process for preparing compounds of formula (I), wherein the last step of the process comprises the use of formamide for the formation of the imidazole ring.
  • the use of formamide requires severe reaction conditions, which should be avoided in connection with industrial production in large scale.
  • the individual steps of the process according to the present invention are known as such (see e.g. EP 0 146 228 B1), it has now surprisingly been found that compounds of formula (I) can be prepared, also in large scale, in very good yields by using the synthesis route described below.
  • the present invention relates to a process for preparing substituted imidazole derivatives of formula (I) and acid addition salts thereof
  • Y, R-i, R 2 and R 3 are as defined above and X is halogen, with an amine of formula R 4 NH 2 , wherein R 4 is an easily removable leaving group, and an alkali metal thiocyanate.
  • the invention also relates to intermediate compound (IV) wherein Y, R-i, R 2 , R 3 and R are as defined above.
  • an acid addition salt refers to an addition salt of any pharmaceutically acceptable acid, preferably hydrochloric or hydrobromic acid.
  • halogen refers to F, CI, Br and I.
  • Ri and/or R 2 it preferably refers to F and/or CI, and most preferably to F.
  • X it preferably refers to CI and Br, and most preferably to Br.
  • lower alkyl refers to a monoradical branched or unbranched saturated hydrocarbon chain having from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms and most preferably 1 or 2 carbon atoms.
  • aralkyl refers to substituted or unsubstituted groups -alkylene-aryl.
  • Alkylene refers to a diradical of a branched or unbranched saturated hydrocarbon chain, preferably having from 1 to 10 carbon atoms and more preferably having 1 to 6 carbon atoms and aryl refers to an unsaturated aromatic carbocyclic group of from 6 to 20 carbon atoms having a single ring (e.g. phenyl) or multiple condensed (fused) rings (e.g. naphthyl or anthryl).
  • eas/7y removable leaving group refers to any group that a person skilled in the art would know to be easily removable.
  • Preferred easily removable leaving groups would be aralkyls, e.g. benzyl.
  • a compound of formula (II) is, in step a), halogenated with a halogenating agent to obtain a compound of formula (III), where X is a halogen, e.g. Br, CI or I.
  • a preferred halogenating agent is Br 2 .
  • the reaction is suitably carried out in a solvent, such as an alcohol, e.g. methanol, at room temperature or below.
  • a suitable temperature is -8 °C to +25 °C, preferably -8 °C to -5 °C.
  • step b) the compound of formula (111) obtained in step a) is reacted with an amine of formula R 4 NH 2 where R 4 is a easily removable leaving group, and an alkali metal thiocyanate to obtain a mercapto compound of formula (IV).
  • the reaction is suitably carried out in a solvent, such as as an alcohol, e.g. ethanol or butanol, at an elevated temperature, preferably at reflux temperature.
  • the amine for the reaction may be one where R 4 is aralkyl, preferably benzyl.
  • a preferred alkali metal thiocyanat is potassium thiocyanate.
  • step c) the mercapto group is removed from the compound of formula (IV) obtained in step c) to obtain a compound of formula (V).
  • the reaction is suitably carried out in the presence of a catalyst, e.g Raney-Nickel, at a temperature of 40 °C to 90 °C, preferably 40 °C to 60 °C.
  • the group R 4 can be removed from the compound of formula (V) obtained in step c) by treating the compound of formula (V) with ammonium formate in the presence of a catalyst, such as Pd/C.
  • a catalyst such as Raney-Nickel
  • R 4 may be removed by hydrogenation in the presence of Pd/C.
  • the resulting compound of formula (I) may be converted into acid addition salts using methods known per se. Preferred acid addition salts are HCI and HBr.
  • Preferred compounds of formulae (I) to (V) are those where Y is CH 2) Ri is F, R 2 is H and R 3 is ethyl.
  • the process according to the present invention makes it possible to prepare compounds of formula (I) in good yield and in a simple way, e.g. by using lower reaction temperatures, that also are suitable for large-scale production.
  • the known methods result in poor yields and require severe reaction conditions, e.g. high temperatures, which makes large-scale production difficult.
  • HPLC-MS 285-286-287 (68, M+, Br-isotopes), 205 (72), 187 (100).
  • the reaction mixture was evaporated to dryness before 150 ml ethyl acetate was added and the solution was washed with water.
  • the organic phase was dried over Na 2 S0 4 , filtered and evaporated providing 1 ,13 g of 1 -benzyl-5-(2-ethyl-5- fluoro-indan-2-yl)-imidazole-2-thiol (yield 31 %).
  • the analytical sample was purified using TLC-plates. The purity was measured by HPLC: 62 %. Normally the crude product was used in the following step.
  • Example 3 1 -benzyl-5-(2-ethyl-5-f luoro-indan-2-yl)-imidazole
  • a HCI/methanol reagent was prepared by bubbling HCI-gas through methanol.
  • 100 mg of 4-(2-ethyl-5-fluoro-indan-2-yl)-1 H-imidazole was dissolved in 2 ml methanol in a round-bottomed flask.
  • 2 ml of HCI/methanol reagent (3 M) was added slowly to the solution while stirring.
  • the internal temperature of the mixture was kept below 29 °C by cooling.
  • the resulting mixture was evaporated at a temperature between 35 °C and 40 °C to viscous colourless oil whereupon it was dissolved in 2 ml of acetone at the same temperature.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

The invention relates to a process for preparing substituted imidazole derivatives of formula (I) and acid addition salts thereof (I) in which formula Y is -CH2- or -CO-, R1 is H, halo or hydroxy, R2 is H or halo and R3 is H or lower alkyl, starting from a compound of formula (II) wherein Y, R1, R2 and R3 are as defined above. The invention also relates to intermediates and their preparation.

Description

PROCESS FOR PREPARING SUBSTITUTED IMIDAZOLE DERIVATIVES AND INTERMEDIATES USED IN THE PROCESS
FIELD OF THE INVENTION The present invention relates to a new process for preparing substituted imidazole derivatives of formula (I) and acid addition salts thereof,
Figure imgf000003_0001
in which formula Y is -CH2- or -CO-, Ri is H, halogen or hydroxy, R2 is H or halogen and R3 is H or lower alkyl.
The invention also relates to intermediates used in the process and to their preparation.
BACKGROUND OF THE INVENTION
The compounds of the above-mentioned formula (I) are highly selective and long-acting antagonists of α2-adrenoceptors and they have a good peroral bioavailability. The compounds are especially valuable in the treatment of cognitive disorders. Compounds of formula (I) have been described in patent publication EP 0 618 906 B1. Specific examples of such compounds are 4-(2-ethyl-5-fluoroindan-2-yl)-1 H-imidazole and 4-(5- fluoroindan-2-yl)-1 H-imidazole.
The above-mentioned publication EP 0 618 906 B1 also discloses methods of preparing compounds of formula (I). Said methods relate to various ways of modifying the substituents in the benzene moiety of the indan ring system. There is no disclosure of a total synthesis, which would lead to the desired compounds in good yield.
Publication EP 0 310 745 B1 discloses a process for preparing compounds of formula (I), wherein the last step of the process comprises the use of formamide for the formation of the imidazole ring. The use of formamide, however, requires severe reaction conditions, which should be avoided in connection with industrial production in large scale. Although the individual steps of the process according to the present invention are known as such (see e.g. EP 0 146 228 B1), it has now surprisingly been found that compounds of formula (I) can be prepared, also in large scale, in very good yields by using the synthesis route described below.
SUMMARY OF THE INVENTION
The present invention relates to a process for preparing substituted imidazole derivatives of formula (I) and acid addition salts thereof
Figure imgf000004_0001
in which formula Y is -CH2- or-CO-, Ri is H, halogen or hydroxy, R2 is H or halogen and R3 is H or lower alkyl, comprising the steps of a) halogenating a compound of formula (II)
Figure imgf000004_0002
wherein Y, R-t, R2 and R3 are as defined above, to obtain a compound of formula (III)
Figure imgf000004_0003
wherein Y, R-i, R2 and R3 are as defined above and X is halogen, b) reacting the compound of formula (III) thus obtained with an amine of formula R NH2, wherein R4 is an easily removable leaving group, and an alkali metal thiocyanate, to obtain a compound of formula (IV)
Figure imgf000005_0001
wherein Y, R-i, R2, R3 and R4 are as defined above, c) removing the mercapto group from the compound of formula (IV) to obtain a compound of formula (V)
Figure imgf000005_0002
wherein Y, Ri, R2, R3 and R are as defined above, d) removing the group R from the compound of formula (V) to obtain a compound of formula (I), and, if desired, e) converting the resulting compound of formula (I) into an acid addition salt thereof. Further the invention relates to a process for preparing a compound of formula (IV)
Figure imgf000005_0003
wherein Y is -CH2- or -CO-, Ri is H, halogen or hydroxy, R2 is H or halogen and R3 is H or lower alkyl, comprising reacting a compound of formula (III)
Figure imgf000006_0001
wherein Y, R-i, R2 and R3 are as defined above and X is halogen, with an amine of formula R4NH2, wherein R4 is an easily removable leaving group, and an alkali metal thiocyanate.
The invention also relates to intermediate compound (IV) wherein Y, R-i, R2, R3 and R are as defined above.
DETAILED DESCRIPTION OF THE INVENTION
In this context, the term an acid addition salt refers to an addition salt of any pharmaceutically acceptable acid, preferably hydrochloric or hydrobromic acid.
In this context, the term halogen refers to F, CI, Br and I. Regarding Ri and/or R2 it preferably refers to F and/or CI, and most preferably to F. Regarding X it preferably refers to CI and Br, and most preferably to Br.
In this context, the term lower alkyl refers to a monoradical branched or unbranched saturated hydrocarbon chain having from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms and most preferably 1 or 2 carbon atoms.
In this context the term aralkyl refers to substituted or unsubstituted groups -alkylene-aryl. Alkylene refers to a diradical of a branched or unbranched saturated hydrocarbon chain, preferably having from 1 to 10 carbon atoms and more preferably having 1 to 6 carbon atoms and aryl refers to an unsaturated aromatic carbocyclic group of from 6 to 20 carbon atoms having a single ring (e.g. phenyl) or multiple condensed (fused) rings (e.g. naphthyl or anthryl).
In this context the term eas/7y removable leaving group refers to any group that a person skilled in the art would know to be easily removable. Preferred easily removable leaving groups would be aralkyls, e.g. benzyl.
According to the present invention a compound of formula (II) is, in step a), halogenated with a halogenating agent to obtain a compound of formula (III), where X is a halogen, e.g. Br, CI or I. A preferred halogenating agent is Br2. The reaction is suitably carried out in a solvent, such as an alcohol, e.g. methanol, at room temperature or below. A suitable temperature is -8 °C to +25 °C, preferably -8 °C to -5 °C.
In step b) the compound of formula (111) obtained in step a) is reacted with an amine of formula R4NH2 where R4 is a easily removable leaving group, and an alkali metal thiocyanate to obtain a mercapto compound of formula (IV). The reaction is suitably carried out in a solvent, such as as an alcohol, e.g. ethanol or butanol, at an elevated temperature, preferably at reflux temperature. The amine for the reaction may be one where R4 is aralkyl, preferably benzyl. A preferred alkali metal thiocyanat is potassium thiocyanate.
In step c) the mercapto group is removed from the compound of formula (IV) obtained in step c) to obtain a compound of formula (V). The reaction is suitably carried out in the presence of a catalyst, e.g Raney-Nickel, at a temperature of 40 °C to 90 °C, preferably 40 °C to 60 °C. In step d) the group R4 can be removed from the compound of formula (V) obtained in step c) by treating the compound of formula (V) with ammonium formate in the presence of a catalyst, such as Pd/C. Alternatively a catalyst, such as Raney-Nickel, may be used, or R4 may be removed by hydrogenation in the presence of Pd/C. The resulting compound of formula (I) may be converted into acid addition salts using methods known per se. Preferred acid addition salts are HCI and HBr.
Preferred compounds of formulae (I) to (V) are those where Y is CH2) Ri is F, R2 is H and R3 is ethyl. The process according to the present invention makes it possible to prepare compounds of formula (I) in good yield and in a simple way, e.g. by using lower reaction temperatures, that also are suitable for large-scale production. The known methods result in poor yields and require severe reaction conditions, e.g. high temperatures, which makes large-scale production difficult. For instance, compared to the process using formamide (EP 0 310 745 B1), the process of the present invention using lower temperatures does not create separation or isolation problems relating to great amounts of various impurities that are typically formed in the known formamide process The following examples illustrate the invention, but are not intended to restrict the scope of the invention. Example 1
2-bromo-1-(2-ethyl-5-fluoro-indan-2-yl)-ethanone
3,8 g of 2-acetyl-2-ethyl-5-fluoroindan and 35 ml of methanol were placed into a round-bottomed flask equipped with a thermometer, a mechanical stirrer and a dropping funnel. The reaction mixture was cooled in a cooling bath while stirring to a temperature between -5 °C and -8 °C and 0,7 ml of a Br2-solution in a small amount of methanol was added dropwise. The cooling bath was removed and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was cooled to a temperature between -5 °C and -8 °C and an additional 0,175 ml of Br2-solution in a small amount of methanol was added dropwise. The cooling bath was removed and the reaction mixture was stirred at room temperature for an additional 1 to 2 hours. After chromatographic purification using methylene chloride as an eluent 2,51 g of 2-bromo-1-(2-ethyl-5-fluoro-indan-2-yl)-ethanone was obtained as a liquid (yield 69 %).
1 H NMR (200 MHz, CDCI3, ppm): 0.85 (3H, t, J 7.6 Hz, CH2CH3), 1.82 (2H, q, J 7.5 Hz, CH2CH3), 2.83-2.93 (2 H, dd, the indan ring H2-1 or H2-3), 3.32-3.46
(2 H, dd, the indan ring H2-1 or H2-3), 4.11 (2H, s, CH2-Br), 6.79-7.10 (3H, m,
Ar-H)
HPLC-MS: 285-286-287 (68, M+, Br-isotopes), 205 (72), 187 (100).
UV (Lambda-max): 208 nm (Abs. 1.01020 AU), 271 nm (Abs. 0.27428 AU), 277 nm (Abs. 0.27026 AU).
Example 2
1-benzyl-5-(2-ethyl-5-fluoro-indan-2-yl)-imidazole-2-thiol
1 ,62 g of 2-bromo-1-(2-ethyl-5-fluoro-indan-2-yl)-ethanone was dissolved in 25 ml of ethanol in a glass round-bottomed flask equipped with a mechanical stirrer, a thermometer and a dropping funnel. The reaction mixture was heated to reflux temperature while stirring. 0.366 g of benzylamine dissolved in 5 ml ethanol was added slowly in a drop-wise fashion to the solution. After the addition of benzylamine the mixture was refluxed for one hour. 0,330 g of potassium thiocyanate was added portionwise during 30 minutes and the reaction mixture was refluxed for 2 hours. The reaction mixture was evaporated to dryness before 150 ml ethyl acetate was added and the solution was washed with water. The organic phase was dried over Na2S04, filtered and evaporated providing 1 ,13 g of 1 -benzyl-5-(2-ethyl-5- fluoro-indan-2-yl)-imidazole-2-thiol (yield 31 %). The analytical sample was purified using TLC-plates. The purity was measured by HPLC: 62 %. Normally the crude product was used in the following step.
1 H NMR (200 MHz, CDCI3, ppm): 0.75 (t, CH2Ch ), 1.80 (q, CHgCHs), 2.81- 3.30 (m, the indan ring H2-1 and H2-3), 5.18 (s, N-CHg-Ar), 6.24 (s, -SH), 6.77- 7.09 (m, Ar-H, im-H), 7.23-7.36 (m, Ar-H-CH2-N). HPLC-MS: 353 (100, M+), 221 (29), 187 (12).
Example 3 1 -benzyl-5-(2-ethyl-5-f luoro-indan-2-yl)-imidazole
7,5 ml of Raney-Nickel prepared according to Vogel, Practical Organic Chemistry, 5th Edition, 1999, Longman, U.K. p. 450-451 , was mixed with 20 ml of ethanol under nitrogen atmosphere in a round-bottomed flask equipped with a thermometer and a stirring bar. 500 mg of 1 -benzyl-5-(2-ethyl- 5-fluoro-indan-2-yl)-imidazole-2-thiol was dissolved in 10 ml of ethanol and added to the mixture. The reaction mixture was stirred at 40 °C for about 10 hours and then the temperature was raised to 60 °C for 2 hours followed by cooling to room temperature. The mixture was filtered and the filter (Celite™) was washed with ethanol. The ethanol solution was evaporated to dryness to obtain 151 mg of a crude product. After chromatographic purification using methylene chloride, methylene chloride-methanol (10:1 ) and methylene chloride-methanol (1 :1) as eluents 1-benzyl-5-(2-ethyl-5-fluoro-indan-2-yl)- imidazole was obtained. The purity was measured by HPLC: 83 %.
1 H NMR (200 MHz, MeOD, ppm): 0.70 (3H, t, CH2CH3), 1.82 (2H, q, CH^CHs), 2.90-3.01 (2 H, dd, the indan ring H2-1 or H2-3), 3.13-3.25 (2 H, dd, the indan ring H2-1 or H2-3), 5.10 (2H, s, N-CHz-Ar), 6.72-6.87 (3H, m, Ar-H, im-H), 7.05- 7.18 (3H, m, Ar-H, Ar-H-CH2-N), 7.29-7.32 (3H, m, Ar-H-CH2-N), 7.56 (1 H, s, im-H).
HPLC-MS: 321 (100, M+). Example 4
4-(2-ethyl-5-fluoro-indan-2-yl)-1 H-imidazole
53 mg of 1-benzyl-5-(2-ethyl-5-fluoro-indan-2-yl)-imidazole, 20 mg of Pd/C, 51 mg of ammonium formate and 2 ml of ethanol were added under nitrigen atmosphere into a round-bottomed flask equipped with a thermometer and a stirring bar. The reaction mixture was stirred at reflux temperature for 6 hours. The mixture was filtered and the filter (Celite™) was washed with ethanol. The reaction mixture was placed back into a round-bottomed flask and an additional 20 mg of Pd/C and 51 mg of ammonium formate were added under nitrogen atmosphere. The mixture was heated to reflux temperature and refluxed for 2 hours. Then the mixture was cooled to room temperature and filtered. The filter (Celite™) was washed with ethanol and after evaporation to dryness, whereby 4-(2-ethyl-5-fluoro-indan-2-yl)-1 H-imidazole was obtained. The analytical sample was purified using TLC-plates. The purity was measured by HPLC: 60 %. Normally the crude product was used in the following step.
1 H NMR (200 MHz, MeOD, ppm): 0.76 (t, CHsCh ), 1.29 (q, CHgC 3), 2.98- 3.22 (m, the indan ring H2-1 and H2-3), 6.78-6.94 (m, Ar-H, im-H), 7.09-7.19 (m, Ar-H, im-H). HPLC-MS: 231 (100, M+).
Example 5 4-(2-ethyl-5-fluoro-indan-2-yl)-1 H-imidazole
10 ml of the crude product obtained in Example 3 was placed in a round-bottomed flask equipped with a thermometer and a stirring bar. 1 ,5 ml of Raney-Nickel in ethanol (Raney-Nickel prepared according to Vogel, Practical Organic Chemistry, 5th Edition, 1999, Longman, U.K. p. 450-451), was added under nitrogen atmosphere. The reaction mixture was stirred at reflux temperature for about 14 hours. After filtration and evaporation crude 4-(2- ethyl-5-fluoro-indan-2-yl)-1 H-imidazole was obtained.
HPLC-MS: 231 (100, M+). Example 6
4-(2-ethyl-5-fluoro-indan-2-yl)-1 H-imidazole-hydrochloride
A HCI/methanol reagent was prepared by bubbling HCI-gas through methanol. 100 mg of 4-(2-ethyl-5-fluoro-indan-2-yl)-1 H-imidazole was dissolved in 2 ml methanol in a round-bottomed flask. 2 ml of HCI/methanol reagent (3 M) was added slowly to the solution while stirring. During the addition the internal temperature of the mixture was kept below 29 °C by cooling. The resulting mixture was evaporated at a temperature between 35 °C and 40 °C to viscous colourless oil whereupon it was dissolved in 2 ml of acetone at the same temperature. The solution was cooled to a temperature between 10 °C and 15 °C at which temperature the mixture started to crystallize. The crystalline material was filtered, washed with cooled acetone and dried in a vacuum oven at 35 °C overnight. A second crop was isolated from the mother liquid followed by cooling, filtering and drying as described above. The yield of 4-(2-ethyl-5-fluoro-indan-2-yl)-1 H-imidazole-hydrochloride was altogether 87% of the theoretical, m.p. 171 - 173 °C.

Claims

Claims
1. A process for prepaπng substituted imidazole derivatives of formula (I) and acid addition salts thereof
Figure imgf000012_0001
(I)
in which formula Y is -CH2- or -CO-, R-i is H, halogen or hydroxy, R2 is H or halogen and R3 is H or lower alkyl, comprising the steps of a) halogenating a compound of formula (II)
Figure imgf000012_0002
wherein Y, Ri, R2 and R3 are as defined above, to obtain a compound of formula (III)
Figure imgf000012_0003
wherein Y, R-i, R2 and R3 are as defined above and X is halogen, b) reacting the compound of formula (III) thus obtained with an amine of formula R4NH2, wherein R4 is an easily removable leaving group, and an alkali metal thiocyanate, to obtain a compound of formula (IV)
Figure imgf000013_0001
wherein Y, Ri, R2 , R3 and R4 are as defined above, c) removing the mercapto group from the compound of formula (IV) to obtain a compound of formula (V)
Figure imgf000013_0002
wherein Y, Ri, R2 , R3 and R4 are as defined above, d) removing the group R4 from the compound of formula (V) to obtain a compound of formula (I), and, if desired, e) converting the resulting compound of formula (I) into an acid addition salt thereof.
2. A process according to claim 1 wherein step a) is carried by reacting a compound of formula (II) with Br2 in methanol at a temperature of - 8 to +25 °C.
3. A process according to claim 1 or 2 wherein step b) is carried out by reacting a compound of formula (III) with benzylamine and potassium thiocyanate.
4. A process according to any of claims 1 to 3 wherein step c) is carried out in the presence of Raney-Nickel at a temperature of 40 °C to 90 °C.
5. A process according to any of claims 1 to 4 wherein step d) is carried out by using ammonium formate in the presence of Pd/C.
6. A process according to any of claims 1 to 4 wherein step d) is carried out by hydrogenation in the presence of Pd/C.
7. A process according to any of claims 1 to 6 wherein Y is -CH2-,
Ri is F, R2 is H and R3 is ethyl.
8. A process for preparing a compound of formula (IV)
Figure imgf000014_0001
wherein Y is -CH2- or -CO-, Ri is H, halogen or hydroxy, R2 is H or halogen and R3 is H or lower alkyl, comprising reacting a compound of formula (111)
Figure imgf000014_0002
wherein Y, Ri, R2 and R3 are as defined above and X is halogen, with an amine of formula R4NH2, wherein R is an easily removable leaving group, and an alkali metal thiocyanate.
9. A process according to claim 8 comprising reacting a compound of formula (III) with benzylamine and potassium thiocyanate.
10. A process according to claim 8 or 9 wherein Y is -CH2-, Ri is F, R2 is H and R3 is ethyl.
11. A compound of formula (IV)
Figure imgf000015_0001
wherein Y is -CH2- or -CO-, Ri is halogen or hydroxy, R2 is H or halogen, R3 is H or lower alkyl and R is an easily removable leaving group.
12. A compound according to claim 11 wherein Y is -CH2-, Ri is F, R2 is H, R3 is ethyl and R4 is benzyl.
PCT/FI2004/000004 2003-01-08 2004-01-08 Process for preparing substituted imidazole derivatives and intermediates used in the process WO2004063168A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
DE602004020050T DE602004020050D1 (en) 2003-01-08 2004-01-08 METHOD FOR PRODUCING SUBSTITUTED IMIDAZOLE DERIVATIVES AND INTERMEDIATES USED IN THE PROCESS
CA2511969A CA2511969C (en) 2003-01-08 2004-01-08 Process for preparing substituted imidazole derivatives and intermediates used in the process
US10/537,177 US7223871B2 (en) 2003-01-08 2004-01-08 Process for preparing substituted imidazole derivatives and intermediates used in the process
MXPA05007217A MXPA05007217A (en) 2003-01-08 2004-01-08 Process for preparing substituted imidazole derivatives and intermediates used in the process.
AU2004203941A AU2004203941B2 (en) 2003-01-08 2004-01-08 Process for preparing substituted imidazole derivatives and intermediates used in the process
JP2006500148A JP4592680B2 (en) 2003-01-08 2004-01-08 Process for producing substituted imidazole derivatives and intermediates used in the process
BR0406676-6A BRPI0406676A (en) 2003-01-08 2004-01-08 Process for preparing substituted imidazole derivatives to prepare a compound and resulting compound
EP04700707A EP1581504B1 (en) 2003-01-08 2004-01-08 Process for preparing substituted imidazole derivatives and intermediates used in the process
DK04700707T DK1581504T3 (en) 2003-01-08 2004-01-08 Process for preparing substituted imidazole derivatives and intermediates used in the process
NZ539831A NZ539831A (en) 2003-01-08 2004-01-08 Process for preparing substituted imidazole derivatives and intermediates used in the process
IL168452A IL168452A (en) 2003-01-08 2005-05-05 Process for preparing substituted imidazole derivatives and intermediates used in the process
NO20053712A NO330965B1 (en) 2003-01-08 2005-08-01 Process for Preparation of Substituted Imidazole Derivatives, Intermediates Used in the Process, and Process for Preparation of Intermediate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20030026 2003-01-08
FI20030026A FI116292B (en) 2003-01-08 2003-01-08 Process for the preparation of substituted imidazole derivatives and in the process useful intermediates

Publications (1)

Publication Number Publication Date
WO2004063168A1 true WO2004063168A1 (en) 2004-07-29

Family

ID=8565279

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2004/000004 WO2004063168A1 (en) 2003-01-08 2004-01-08 Process for preparing substituted imidazole derivatives and intermediates used in the process

Country Status (21)

Country Link
US (1) US7223871B2 (en)
EP (1) EP1581504B1 (en)
JP (1) JP4592680B2 (en)
KR (1) KR101079065B1 (en)
CN (1) CN100339368C (en)
AT (1) ATE425972T1 (en)
AU (1) AU2004203941B2 (en)
BR (1) BRPI0406676A (en)
CA (1) CA2511969C (en)
DE (1) DE602004020050D1 (en)
DK (1) DK1581504T3 (en)
ES (1) ES2322463T3 (en)
FI (1) FI116292B (en)
IL (1) IL168452A (en)
MX (1) MXPA05007217A (en)
NO (1) NO330965B1 (en)
NZ (1) NZ539831A (en)
PL (1) PL213564B1 (en)
PT (1) PT1581504E (en)
RU (1) RU2329253C2 (en)
WO (1) WO2004063168A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071584A1 (en) * 2007-12-05 2009-06-11 Grindeks, A Joint Stock Company Process for the preparation of 5-(2-ethyl-dihydro-1h-inden-2-yl)-1h-imidazole and salts thereof
WO2011009928A1 (en) * 2009-07-24 2011-01-27 Dsm Pharma Chemicals Regensburg Gmbh Indane derivatives for use as intermediates
WO2011014613A3 (en) * 2009-07-31 2011-06-03 Dr. Reddy's Laboratories Ltd. Preparation of fipamezole
WO2012123129A1 (en) * 2011-03-17 2012-09-20 Santhera Pharmaceuticals (Schweiz) Ag Solid state crystalline forms of 4-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146228A1 (en) * 1983-10-18 1985-06-26 Farmos-Yhtyma Oy Substituted 2-mercapto-imidazoles and their preparation and use
EP0310745A2 (en) * 1984-11-23 1989-04-12 Orion-Yhtymä Oy Substituted imidazole derivatives and their preparation and use
WO2003099795A1 (en) * 2002-05-21 2003-12-04 Allergan, Inc. 4-substituted imidazole-2-thiones and imidazol-2-ones as agonists of the alpha-2b and alpha-2c adrenergic receptors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1372551A (en) 1999-09-06 2002-10-02 株式会社Lgci Process for preparing 1-substituted 5-hydroxymethyl imidazole

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146228A1 (en) * 1983-10-18 1985-06-26 Farmos-Yhtyma Oy Substituted 2-mercapto-imidazoles and their preparation and use
EP0310745A2 (en) * 1984-11-23 1989-04-12 Orion-Yhtymä Oy Substituted imidazole derivatives and their preparation and use
WO2003099795A1 (en) * 2002-05-21 2003-12-04 Allergan, Inc. 4-substituted imidazole-2-thiones and imidazol-2-ones as agonists of the alpha-2b and alpha-2c adrenergic receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHAUMANN: "Houben-Weyl Teil 3 - E8C", 1994, GEORG THIEME VERLAG, STUTTGART, XP002282560 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071584A1 (en) * 2007-12-05 2009-06-11 Grindeks, A Joint Stock Company Process for the preparation of 5-(2-ethyl-dihydro-1h-inden-2-yl)-1h-imidazole and salts thereof
JP2011506284A (en) * 2007-12-05 2011-03-03 グリンデクス，ア ジョイント ストック カンパニー Method for preparing 5- (2-ethyldihydro-1H-inden-2-yl) -1H-imidazole and salts thereof
EA016832B1 (en) * 2007-12-05 2012-07-30 Гриндекс, Джоинт Сток Кампани Process for the preparation of 5-(2-ethyl-2,3-dihydro-1h-inden-2-yl)-1h-imidazole and salts thereof
WO2011009928A1 (en) * 2009-07-24 2011-01-27 Dsm Pharma Chemicals Regensburg Gmbh Indane derivatives for use as intermediates
US8563766B2 (en) 2009-07-24 2013-10-22 Dsm Pharma Chemicals Indane derivatives for use as intermediates
WO2011014613A3 (en) * 2009-07-31 2011-06-03 Dr. Reddy's Laboratories Ltd. Preparation of fipamezole
EP2459540A2 (en) * 2009-07-31 2012-06-06 Dr. Reddy's Laboratories, Ltd. Preparation of fipamezole
EP2459540A4 (en) * 2009-07-31 2012-12-19 Reddys Lab Ltd Dr Preparation of fipamezole
WO2012123129A1 (en) * 2011-03-17 2012-09-20 Santhera Pharmaceuticals (Schweiz) Ag Solid state crystalline forms of 4-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole
EP2502917A1 (en) * 2011-03-17 2012-09-26 Santhera Pharmaceuticals (Schweiz) AG Solid state crystalline forms of 4-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-1H-imidazole

Also Published As

Publication number Publication date
AU2004203941A1 (en) 2004-07-29
FI20030026A (en) 2004-07-09
PL378179A1 (en) 2006-03-06
DE602004020050D1 (en) 2009-04-30
AU2004203941B2 (en) 2009-08-06
RU2005125044A (en) 2006-01-20
JP2006515349A (en) 2006-05-25
ATE425972T1 (en) 2009-04-15
NO20053712L (en) 2005-08-01
EP1581504A1 (en) 2005-10-05
DK1581504T3 (en) 2009-06-29
KR101079065B1 (en) 2011-11-02
CN1723202A (en) 2006-01-18
FI20030026A0 (en) 2003-01-08
BRPI0406676A (en) 2005-12-20
PT1581504E (en) 2009-05-26
CA2511969A1 (en) 2004-07-29
MXPA05007217A (en) 2005-09-12
ES2322463T3 (en) 2009-06-22
NZ539831A (en) 2007-11-30
CN100339368C (en) 2007-09-26
PL213564B1 (en) 2013-03-29
US7223871B2 (en) 2007-05-29
EP1581504B1 (en) 2009-03-18
RU2329253C2 (en) 2008-07-20
FI116292B (en) 2005-10-31
NO330965B1 (en) 2011-08-29
JP4592680B2 (en) 2010-12-01
CA2511969C (en) 2011-10-11
IL168452A (en) 2009-07-20
KR20050091065A (en) 2005-09-14
US20060025465A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
FR2671348A1 (en) NOVEL PHENYLIMIDAZOLIDINES, PROCESS FOR THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME.
RU2718058C2 (en) Synthesis method of rapamycin derivatives
IL168452A (en) Process for preparing substituted imidazole derivatives and intermediates used in the process
JP3378315B2 (en) Carbazolone derivative and method for preparing the same
CZ228793A3 (en) Process for preparing dichloride of l-5(2-acetoxypropionylamino) -2,4,6-triiodoisophthalic acid
KR920002295B1 (en) Process for the preparation of pyrrolidone derivatives
EP0296048B1 (en) Derivatives of piperazinyl alkyl piperazine dione, processes for their preparation and pharmaceutical compositions containing them
FR2534256A1 (en)
US10487062B1 (en) Regioselective one-step process for synthesizing 2-hydroxyquinoxaline
EP0279644B1 (en) Cyanoguanidine derivative and process for preparation thereof
JPH062747B2 (en) Process for producing 2-alkyl-4,5-dihydroxymethylimidazole
WO1999006398A1 (en) 1,3-oxazolinyl-biphenyl derivatives, preparation method and use as synthesis intermediates
BE884977A (en) NOVEL N-PHENYL-BENZAMIDES USEFUL IN THE TREATMENT OF MAMMALIAN INFLAMMATION AND PAIN
EP0259140B1 (en) Cyanoguanidine derivative and process for preparation thereof
CN117088829A (en) Synthesis method of 1-isopropyl-4- (p-methoxyphenyl) piperazine or halogen acid salt thereof
JPH0528708B2 (en)
CN116715635A (en) Synthesis process of 5-n-propyl hydantoin
EP2305650A1 (en) Novel process for the preparation of telmisartan
FR2489824A1 (en) PROCESS FOR THE PREPARATION OF APOVINCAMINIC ACID ESTERS AND PRODUCTS THUS OBTAINED
JPH0586946B2 (en)
JPS58216166A (en) Production of n-substituted imidazole
PL231844B1 (en) Method for obtaining 1,3-bis(2-hydroxyethyl)-4-phenyl-5-[2(2-oxooxazol-3-yl)phenyl]imidazole-2-on
JPH0791279B2 (en) 2-Aminomethyl-5-methylpyrazine and method for producing the same
KR20050036412A (en) A process for preparing carbazolone derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 539831

Country of ref document: NZ

Ref document number: 2004203941

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 168452

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2004203941

Country of ref document: AU

Date of ref document: 20040108

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004203941

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006025465

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10537177

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006500148

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004700707

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 378179

Country of ref document: PL

Ref document number: 2511969

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/A/2005/007217

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1497/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020057012682

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20048019799

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2005125044

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020057012682

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004700707

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0406676

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10537177

Country of ref document: US